The total return over the past 12 months is -61.87% vs. +16.94% for the S&P 500. So far it's up -33.08% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (61.87%) | (68.55%) | (60.04%) | (46.34%) | N/A | N/A |
| Total Return CAGR | (61.87%) | (68.55%) | (60.04%) | (46.34%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Citius Pharmaceuticals, Inc. (CTXR)
| Year | Start price | End price | CTXR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.78 | $0.52 | (33.08%) | +14.51% | (47.59%) |
| 2025 | $4.00 | $0.78 | (80.57%) | +17.72% | (98.29%) |
| 2024 | $18.91 | $4.00 | (78.85%) | +24.89% | (103.74%) |
| 2023 | $19.75 | $18.91 | (4.25%) | +26.19% | (30.44%) |
| 2022 | $38.50 | $19.75 | (48.70%) | (18.17%) | (30.53%) |
| 2021 | $25.50 | $38.50 | +50.98% | +28.74% | +22.24% |
| 2020 | $25.50 | $25.50 | 0.00% | +18.37% | (18.37%) |
| 2019 | $26.00 | $25.50 | (1.92%) | +31.22% | (33.14%) |
| 2018 | $95.00 | $26.00 | (72.63%) | (4.56%) | (68.07%) |
| 2017 | $166.42 | $95.00 | (42.92%) | +21.70% | (64.62%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
